TrialLeukemia & lymphoma2015

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Ryan Mattison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.